logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
Market PulseMarket Pulse
ScreenersScreeners
MoreMore
prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Ind-Swift Laboratories Ltd

Ind-Swift Laboratories

Small Cap•47 Employees•IPO 2002
Current Price
₹145.40
-0.47 (-0.32%)Updated
NSE :INDSWFTLAB
BSE :532305
Sector :Pharmaceuticals
Today's Range
144.5
₹145.40
indicator
148.06
52 Week Range
52W Low₹68.72
52W High₹151.98
₹145.40
indicator
Downside111.58%
Upside4.53%
chart iconChart

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
₹1,171.94 Cr
Market Cap
Total market value of company
P/E Ratio
4.41
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
0.59
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
₹37.15
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
20.73%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
0.78%
ROCE
Return on Capital Employed. >15% is good
Net Margin
32.35%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
-%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
-6.35%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
360.00%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
833.00%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
0.03
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
₹170.63
Book Value
Net asset value per share
Dividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
39.50%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

4 points
  • •The company maintains a very low debt-to-equity ratio of 0.03, indicating a strong financial position with minimal reliance on external debt, which significantly reduces financial risk for investors.
  • •Recent quarterly results show impressive growth, with sales increasing by 360% and net profit surging by 833%, signaling a strong operational turnaround and potential for future earnings.

Weaknesses

5 points
  • •The company exhibits extremely low profitability metrics, with Return on Equity (ROE) at 0.18% and Return on Capital Employed (ROCE) at 0.78%, indicating inefficient use of capital.
  • •Operational efficiency is a major concern, as evidenced by a negative Operating Profit Margin (OPM) of -5.62%, suggesting the company is losing money on its core business activities.

Opportunities

4 points
  • •The company operates within the Pharmaceuticals sector, a robust and growing industry, which provides a favorable external environment for long-term expansion and increased demand for its products.
  • •As a relatively small-cap company with a market cap of 757 Cr, Ind-Swift Laboratories has significant room for growth and market share expansion compared to larger industry peers.

Threats

4 points
  • •The highly competitive Pharmaceuticals sector, dominated by larger, more profitable peers, poses a significant threat to Ind-Swift Laboratories' market share and pricing power.
  • •The company faces inherent risks from stringent and evolving regulatory landscapes in the pharmaceutical industry, which can lead to increased compliance costs and operational hurdles.

Segment-wise Financial Analysis

Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

No insider trading data available

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R4₹154.59+₹9.19+6.32%
R3₹151.03+₹5.63+3.87%
R2₹149.55+₹4.15+2.85%
R1₹147.47+₹2.07+1.43%
PIVOT₹145.990.590.40%
CURRENT₹145.40--
S1₹136.79-₹8.61-5.92%
S2₹140.35-₹5.05-3.47%
S3₹142.43-₹2.97-2.04%
S4₹143.91-₹1.49-1.02%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
2.25L
(18 Mar 2026)
-68.0% vs avg
Delivery %
53.2%
(18 Mar 2026)
+10.3% vs avg
Avg Volume (20D)
7.03L
(18 Feb - 18 Mar)
20-day average
Avg Delivery %
42.9%
(18 Feb - 18 Mar)
Trend ↑
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Wanbury Ltd
1197.00 %
Highest Dividend Yield
Kopran Ltd
2.26 %

Peer Comparison

Company Name
ANUHPHR
Anuh Pharma Ltd
BAJAJHCARE
Bajaj Healthcare Ltd
BETA
Beta Drugs Ltd
JAGSNPHARM
Jagsonpal Pharmaceuticals Ltd
KILITCH
Kilitch Drugs (India) Ltd
KOPRAN
Kopran Ltd
LINCOLN
Lincoln Pharmaceuticals Ltd
MEDICAMEQ
Medicamen Biotech Ltd
NGLFINE
NGL Fine Chem Ltd
SAKAR
Sakar Healthcare Ltd
SIGACHI
Sigachi Industries Ltd
SUNPHARMA
Sun Pharmaceutical Industries Ltd
SYNCOMF
Syncom Formulations (India) Ltd
TTKHLTCARE
TTK Healthcare Ltd
VENUSREM
Venus Remedies Ltd
WANBURY
Wanbury Ltd

About

INDSWFTLAB

Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Limited is a pharmaceutical company based in India that operates both domestically and internationally. Their core business centers around the development, manufacturing, and sale of active pharmaceutical ingredients (APIs), intermediates, and finished pharmaceutical formulations. This encompasses a wide range of therapeutic areas, demonstrating a significant breadth of product offerings.

The company's API portfolio covers a diverse spectrum of therapeutic applications. This includes areas such as antibiotics (macrolides), cardiovascular treatments, antihistamines, antidiabetics, antipsychotics, treatments for bone resorption disorders, Parkinson's disease, hyperparathyroidism, analgesics, aromatase inhibitors, nootropics, antidiarrheals/antiprotozoals, medications for alcohol abstinence, antineoplastics (anticancer agents), treatments for ADHD symptoms, hypercholesterolemia, antimigraine medications, and thrombocytopenia treatments. This extensive range highlights the company's commitment to addressing a broad array of medical needs.

Beyond APIs, Ind-Swift Laboratories also provides reference standards and impurities for a substantial list of pharmaceuticals. This includes key compounds across various therapeutic classes, supporting the quality control and analytical needs of other pharmaceutical manufacturers. The list of provided reference standards and impurities indicates a significant investment in analytical capabilities and a commitment to high-quality product development.

Further expanding its services, Ind-Swift Laboratories offers contract research and manufacturing services (CRAMS). This aspect of their business allows them to provide customized solutions and support to other pharmaceutical companies, leveraging their expertise in development and manufacturing to aid in the production of other companies’ drugs. This demonstrates a versatile business model that incorporates both internal product development and external partnerships.

In summary, Ind-Swift Laboratories Limited is a multifaceted pharmaceutical company with a strong focus on API manufacturing and a diversified portfolio of products and services. Their global reach, extensive range of therapeutic areas covered, and provision of CRAMS position them as a significant player in the Indian and international pharmaceutical landscape. The company's history, starting in 1995, suggests a considerable amount of experience and established processes within the industry.

COMPANY FACTS - INDSWFTLAB

Registered Address

SCO 850, NAC, Shivalik Enclave,, Manimajra

Chandigarh

CHANDIGARH

IN

Tel: 911725061850

Website:https://www.indswiftlabs.com/

Investor Relations:http://www.indswiftlabs.com/investor
Company Details

Group: Pharmaceuticals, Biotechnology & Life Sciences

Sector: Health Care

Industry: Pharmaceuticals

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 47

IPO Date: 15/03/2002

MANAGEMENT - INDSWFTLAB

Shri. Navrattan Munjal

Executive Chairman of the Board, Managing Director

Mr. Gagan Aggarwal

Chief Financial Officer

Shri. Vikas Narendra

President - US Operations

Rakesh Bahuguna

Senior Vice President - QC

Anurag Chaturvedi

Senior Vice President - Marketing

Varun Chhabra

Senior Vice President - Marketing

Ashok Prasad

Senior Vice President - R&D

Sandeep Singh

Senior Vice President - Procurement

Saranjai Tyagi

Senior Vice President - QA

Shri. Pardeep Verma

Compliance Officer, Company Secretary, AVP - Corporate Affairs

Shri. Himanshu Jain

Joint Managing Director, Whole Time Director

Shri. Rishav Mehta

Whole Time Director

Investor Questions Answered

Ind-Swift Laboratories Ltd (INDSWFTLAB) Stock FAQs

Get answers to the most common questions about Ind-Swift Laboratories Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Ind-Swift Laboratories Ltd (INDSWFTLAB) is ₹145.4. Today, the stock has declined by ₹0.47 (0.32%), trading in a range of ₹144.5 to ₹148.06. The stock opened at ₹145.87 with a trading volume of 2,25,193 shares.
Ind-Swift Laboratories Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,171.94 crores, P/E ratio of 4.41, ROE of 20.73%, and ROCE of 0.78%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Ind-Swift Laboratories Ltd (INDSWFTLAB) is ₹151.98, while the 52-week low is ₹68.72. Currently trading at ₹145.4, the stock is 92.1% away from its 52-week low and 4.3% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Ind-Swift Laboratories Ltd stock at ₹145.4 depends on multiple factors. The stock is currently trading with a P/E ratio of 4.41 and P/B ratio of N/A. Today's performance shows a loss of 0.32%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Ind-Swift Laboratories Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹145.4, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Ind-Swift Laboratories Ltd's key financial metrics include: P/E Ratio: 4.41, P/B Ratio: N/A, ROE: 20.73%, ROCE: 0.78%, Dividend Yield: 0.00%, EPS: ₹37.15, Book Value: ₹170.63, Debt-to-Equity: 0.03, and Current Ratio: N/A. The company's market cap stands at ₹1,171.94 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Ind-Swift Laboratories Ltd stock opened at ₹145.87 and is currently trading at ₹145.4, showing a decline of ₹0.47 (0.32%). The intraday high is ₹148.06 and low is ₹144.5. The trading volume stands at 2,25,193 shares, indicating moderate market participation today.
Ind-Swift Laboratories Ltd has a Price-to-Earnings (P/E) ratio of 4.41, which means investors are willing to pay ₹4.41 for every ₹1 of earnings. With an EPS of ₹37.15, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
Ind-Swift Laboratories Ltd has a market capitalization of ₹1,171.94 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹145.4) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Ind-Swift Laboratories Ltd has a book value of ₹170.63 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹145.4, which is 14.8% below the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Ind-Swift Laboratories Ltd has a Return on Equity (ROE) of 20.73% and Return on Capital Employed (ROCE) of 0.78%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Ind-Swift Laboratories Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Ind-Swift Laboratories Ltd has a debt-to-equity ratio of 0.03, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Ind-Swift Laboratories Ltd has an Earnings Per Share (EPS) of ₹37.15, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹145.4 and P/E ratio of 4.41, investors are paying 4.41 times the annual earnings per share. This moderate EPS suggests decent earnings generation. Track EPS growth over quarters to assess earnings momentum.
Ind-Swift Laboratories Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Ind-Swift Laboratories Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Ind-Swift Laboratories Ltd stock, consider: 1) Fundamental Analysis - Review P/E (4.41), ROE (20.73%), debt-to-equity (0.03), and growth rates. 2) Technical Analysis - Check 52-week range (₹68.72 - ₹151.98), moving averages, and chart patterns. 3) Valuation - Compare current price (₹145.40) with book value (₹170.63) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Ind-Swift Laboratories Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹145.4 is 1354x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Ind-Swift Laboratories Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹68.72 - ₹151.98). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.03 indicates leverage. 4) Liquidity Risk - Based on trading volume of 2,25,193 shares. 5) Valuation Risk - P/E of 4.41 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Ind-Swift Laboratories Ltd operates in the industry with key metrics: P/E ratio of 4.41, ROE of 20.73%, market cap of ₹1,171.94 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.03), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Ind-Swift Laboratories Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹145.4, with a 52-week range of ₹68.72 to ₹151.98. Based on fundamentals like P/E (4.41), ROE (20.73%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Ind-Swift Laboratories Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹145.40. 2) Fundamental Deterioration - Declining ROE (currently 20.73%), increasing debt (D/E: 0.03), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Ind-Swift Laboratories Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.